Source comparison
Side-by-Side Comparison
Class GHRH analog GHRP (selective ghrelin/GHS-R agonist) Mechanism Synthetic GHRH analog; pituitary GH release with physiological feedback regulation Selective GHSR agonist; pulsatile GH release without raising cortisol, prolactin, or ACTH Evidence Grade A B R
This comparison does not assign a generated winner or score.
- Class
- GHRH analog
- GHRP (selective ghrelin/GHS-R agonist)
- Mechanism
- Synthetic GHRH analog; pituitary GH release with physiological feedback regulation
- Selective GHSR agonist; pulsatile GH release without raising cortisol, prolactin, or ACTH
- Evidence Grade
- A
- B
- Route
- Subcutaneous injection
- Typical Dose
- 2 mg once daily
- 100-300 mcg, 1-3x daily
- Half-Life
- ~26-38 minutes
- ~2 hours
- FDA Status
- Approved (Egrifta, HIV-associated lipodystrophy)
- Not approved; research compound
- Reported Outcomes
- Visceral fat reduction (HIV lipodystrophy trials), improved waist circumference, cognitive improvement (pilot data)
- Selective GH release, improved body composition, enhanced sleep quality
- Reported Side Effects
- Injection site reactions, arthralgia/myalgia, peripheral edema
- Mild water retention, transient head rush post-injection, mild hunger increase
- Storage
- Refrigerate 2-8°C
- Refrigerate 2-8°C once reconstituted; use within 28 days
- Cost (research grade)
- $400-800 brand; $100-200 compounded
- $45-90/month